Tesamorelin from bench to bedside FDA approval

About this episode

This episode discusses the FDA approval of Tesamorelin and its implications in clinical research and peptide science.

This episode is designed for listeners interested in clinical research, peptide science, endocrinology, and translational medicine , offering an evidence-based perspective without speculation or medical advice. Topics include: Tesamorelin peptide mechanism of action Preclinical and animal studies Phase II and Phase III clinical trial data FDA approval and HIV-associated lipodystrophy Growth hormone, IGF-1, and metabolic effects Safety, limitations, and ongoing research

Topics covered

• clinical research
• peptide science
• endocrinology
• translational medicine
• FDA approval
• safety and limitations
• metabolic effects

Keywords

• Tesamorelin
• FDA approval
• clinical trials
• peptide mechanism
• HIV-associated lipodystrophy
• growth hormone
• metabolic effects
• safety
• ongoing research

Mentioned in this episode

Organizations: FDA, HIV-associated lipodystrophy

Products: Tesamorelin, IGF-1

More episodes of Today's discussion on unraveling BPC 157 Peptide

• The secret Hollywood stack · June 5, 2026 · 23 min
• Selank: The Russian Peptide for Calm Focus and Neuroplasticity · May 29, 2026 · 19 min
• MOTS-c, a unique peptide encoded within mitochondrial DNA · May 25, 2026 · 19 min
• SS-31 and the Architecture of Mitochondrial Medicine · March 9, 2026 · 20 min
• Snap-8 Science: A Deep Dive into Peptide Power · February 12, 2026 · 14 min
• FST-344: Scientific Foundations and Therapeutic Potential · February 2, 2026 · 17 min